Literature DB >> 7586112

High-dose vecuronium neuromuscular block: a comparison of arrhythmias and onset of block during sufentanil anaesthesia.

M D Sharpe1, J M Murkin, T Vannelli.   

Abstract

This study compared the heamodynamic effects of sufentanil with those observed following concomitant sufentanil and high-dose vecuronium administration to determine whether vecuronium induces bradyarrhythmias. Sixty coronary artery bypass patients were stratified into beta blocker (n = 30) or non-beta blocker (n = 30) groups and following induction with sufentanil (9 +/- 3 micrograms.kg-1) and midazolam (0.07 +/- 0.04 mg.kg-1), received either succinylcholine 1 mg.kg-1 (SxCh), vecuronium 0.3 mg.kg-1 (Vec 0.3), or vecuronium 0.5 mg.kg-1 (Vec 0.5). Using a Holter ECG monitor, bradyarrhythmias were classified as mild (HR 46-50), moderate (HR 40-45) or severe (HR < 40). In the pre-induction period, there were no differences in the incidence of mild, moderate or severe bradyarrhythmias among the SxCh, Vec 0.3 or Vec 0.5 groups, in either the beta blocker or non-beta blocker groups. Following induction, there were similar reductions in mean heart rate and mean arterial pressure in all three muscle relaxant groups in both the beta and the non-beta blocker groups; however, there was no difference in the incidence of mild, moderate or severe bradyarrhythmias among the SxCh, Vec 0.3 or Vec 0.5 groups. The Vec 0.5 beta blocker group had a higher incidence of mild bradyarrhythmias (32 +/- 36%) than the Vec 0.5 non-beta blocker group (2 +/- 3%, P = 0.017). Using EMG recording, the onset time of maximal neuromuscular block for the Vec 0.3 group (108 +/- 17 sec) was longer (P < 0.05) than the SxCh (76 +/- 21 sec) and Vec 0.5 (82 +/- 13 sec) groups, which were similar.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7586112     DOI: 10.1007/BF03012671

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  24 in total

1.  Neuromuscular and cardiovascular effects of high-dose vecuronium.

Authors:  W C Tullock; P Diana; D R Cook; D H Wilks; B W Brandom; R L Stiller; C A Beach
Journal:  Anesth Analg       Date:  1990-01       Impact factor: 5.108

2.  Large doses of vecuronium and plasma histamine concentrations.

Authors:  J E Cannon; M R Fahey; J Moss; R D Miller
Journal:  Can J Anaesth       Date:  1988-07       Impact factor: 5.063

3.  A clinical study into the possible intrinsic bradycardic activity of vecuronium.

Authors:  D A Cozanitis; O Erkola
Journal:  Anaesthesia       Date:  1989-08       Impact factor: 6.955

4.  Onset and recovery of atracurium and suxamethonium-induced neuromuscular blockade with simultaneous train-of-four and single twitch stimulation.

Authors:  M J Curran; F Donati; D R Bevan
Journal:  Br J Anaesth       Date:  1987-08       Impact factor: 9.166

5.  Asystole associated with vecuronium.

Authors:  D Clayton
Journal:  Br J Anaesth       Date:  1986-08       Impact factor: 9.166

6.  Bradycardia and asystole following the rapid administration of sufentanil with vecuronium.

Authors:  N J Starr; D H Sethna; F G Estafanous
Journal:  Anesthesiology       Date:  1986-04       Impact factor: 7.892

7.  Hemodynamic responses to pancuronium and vecuronium during high-dose fentanyl anesthesia for coronary artery bypass grafting.

Authors:  R Paulissian; M Mahdi; N J Joseph; M R Salem; B Pavlovich; G J Crystal
Journal:  J Cardiothorac Vasc Anesth       Date:  1991-04       Impact factor: 2.628

8.  Cardiovascular effects of pancuronium, vecuronium, and atracurium during induction of anesthesia with sufentanil and lorazepam for myocardial revascularization.

Authors:  M S Dhamee; T Olund; A C Reynolds; J Entress; J Kalbfleisch
Journal:  J Cardiothorac Anesth       Date:  1990-06

9.  The cardiovascular effects of vecuronium (ORG NC45) and pancuronium in patients undergoing coronary artery bypass grafting.

Authors:  R B Morris; M K Cahalan; R D Miller; P L Wilkinson; A L Quasha; S L Robinson
Journal:  Anesthesiology       Date:  1983-05       Impact factor: 7.892

10.  Neuromuscular and vagal blocking actions of pancuronium bromide, its metabolites, and vecuronium bromide (Org NC45) and its potential metabolites in the anaesthetized cat.

Authors:  I G Marshall; A J Gibb; N N Durant
Journal:  Br J Anaesth       Date:  1983-08       Impact factor: 9.166

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.